Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 114

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 114
---
 and their residual effects, natural 
 disasters, or major catastrophic events;                                                                         |

| • |     | adverse macroeconomic conditions or geopolitical events, including the conflict between Ukraine and Russia, the 
 conflict between Israel and Hamas, high levels of inflation, heightened interest rates, and bank failures;      |

| • |     | the impacts of inflation and rising interest rates on our business and operations; and |

| • |     | changes in general market and economic conditions. |

If our quarterly or annual operating results fall below the expectations of investors or securities analysts or any forecasts or guidance we may provide to the market, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide. We believe that quarterly or annual comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. Our stock price may be volatile, which could result in substantial losses for investors purchasing shares in this offering. The market price of our common stock is likely to be volatile and could fluctuate widely in response to many factors, including but not limited to:

| • |     | volatility and instability in the financial and capital markets; |

| • |     | adverse macroeconomic conditions or geopolitical events, including any health epidemics and their residual                                                       
 effects, the conflict between Ukraine and Russia, the conflict between Israel and Hamas, high levels of inflation, heightened interest rates, and bank failures; |

72

| • |     | announcements relating to our product candidate, including the results of clinical trials by us or our 
 collaborators and the timing thereof;                                                                  |

| • |     | announcements by competitors that impact our competitive outlook; |

| • |     | negative developments with respect to our product candidate, or similar products or product candidates with which 
 we compete;                                                                                                       |

| • |     | developments with respect to patents or intellectual property rights; |

| • |     | announcements of technological innovations, new product candidates, new products or new contracts by us or our 
 competitors;                                                                                                   |

| • |     | announcements relating to strategic transactions, including acquisitions, collaborations, licenses, or similar 
 arrangements;                                                                                                  |

| • |     | actual or anticipated variations in our operating results due to the level of development expenses and other 
 factors;                                                                                                     |

| • |     | changes in financial estimates by equities research analysts and whether our earnings (or losses) meet or exceed 
 such estimates;                                                                                                  |

| •